China drugmakers shift marketing to AI platforms as anti-corruption crackdown disrupts hospital sales

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Chinese drugmakers are shifting physician marketing toward AI medical platforms as an anti-corruption crackdown disrupts traditional hospital sales channels. * Alibaba Health is considering sponsored clinical evidence on Hydrion, creating a potential revenue stream from pharmaceutical marketing budgets. * Frost & Sullivan forecasts China’s digital health marketing spending will grow 27.5% annually during 2027–2030, reaching 274.4 billion yuan ($41.1 billion). * Alibaba Health’s survey found 93% of doctors use AI tools, up from about 70% a year earlier. * Platforms risk undermining doctors’ trust if sponsored content influences clinical evidence without sufficient transparency. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tekedia Capital LLC published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.